Immatics appoints CEO
Harpreet Singh is the new CEO of Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies.
Singh was president and CEO of Immatics US and chief scientific officer of the company, having co-founded Immatics. According to management, he has been instrumental in growing the company from a start-up to a leading player in the field of immuno-oncology.
“The board is delighted to appoint Harpreet as CEO to lead Immatics in the next phase of its development, as the company progresses its pipeline of immunotherapy candidates,” says Peter Chambré, chairman. “Harpreet is an exceptional organizational leader and scientist and over the past three years has led the building of the Immatics US organization and creation of Immatics’ clinical pipeline and capabilities in adoptive cellular therapy, as well as guiding the company’s overall scientific development since its early days. We are very excited about the prospects and opportunities for Immatics, with Harpreet as CEO.”
Singh co-founded Immatics in 2000 to translate pioneering scientific discoveries in immunology into highly innovative immunotherapies to impact the lives of cancer patients. Since the foundation, he has helped grow the company from a start-up to a leading biotech player in the field of immuno-oncology.
In 2015, Singh became president and CEO of Immatics US, overseeing all operations of Immatics in Houston to develop next-generation Adoptive Cell Therapies. He is the inventor on numerous granted patents and patent applications and co-author of scientific papers published by peer-reviewed journals including Nature, Nature Medicine, Nature Biotechnology, and Lancet Oncology. He has a Ph.D. in immunology from the University of Tuebingen, Germany.